Organogenesis Holdings Stock Price To Earning
| ORGO Stock | USD 4.02 0.05 1.26% |
Organogenesis Holdings fundamentals help investors to digest information that contributes to Organogenesis Holdings' financial success or failures. It also enables traders to predict the movement of Organogenesis Stock. The fundamental analysis module provides a way to measure Organogenesis Holdings' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Organogenesis Holdings stock.
Organogenesis | Price To Earning |
Organogenesis Holdings Company Price To Earning Analysis
Organogenesis Holdings' Price to Earnings ratio is typically used for current valuation of a company and is one of the most popular ratios that investors monitor daily. Holding a low PE stock is less risky because when a company's profitability falls, it is likely that earnings will also go down as well. In other words, if you start from a lower position, your downside risk is limited. There are also some investors who believe that low Price to Earnings ratio reflects the low pricing because a given company is in trouble. On the other hand, a higher PE ratio means that investors are paying more for each unit of profit.
Current Organogenesis Holdings Price To Earning | 17.12 X |
Most of Organogenesis Holdings' fundamental indicators, such as Price To Earning, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Organogenesis Holdings is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Organogenesis Price To Earning Driver Correlations
Understanding the fundamental principles of building solid financial models for Organogenesis Holdings is extremely important. It helps to project a fair market value of Organogenesis Stock properly, considering its historical fundamentals such as Price To Earning. Since Organogenesis Holdings' main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of Organogenesis Holdings' historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of Organogenesis Holdings' interrelated accounts and indicators.
Click cells to compare fundamentals
Generally speaking, the Price to Earnings ratio gives investors an idea of what the market is willing to pay for the company's current earnings.
| Competition |
Organogenesis Retained Earnings
Retained Earnings |
|
Based on the latest financial disclosure, Organogenesis Holdings has a Price To Earning of 17.12 times. This is 33.75% lower than that of the Biotechnology sector and significantly higher than that of the Health Care industry. The price to earning for all United States stocks is 40.39% higher than that of the company.
Organogenesis Price To Earning Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Organogenesis Holdings' direct or indirect competition against its Price To Earning to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Organogenesis Holdings could also be used in its relative valuation, which is a method of valuing Organogenesis Holdings by comparing valuation metrics of similar companies.Organogenesis Holdings is currently under evaluation in price to earning category among its peers.
Organogenesis Holdings Current Valuation Drivers
We derive many important indicators used in calculating different scores of Organogenesis Holdings from analyzing Organogenesis Holdings' financial statements. These drivers represent accounts that assess Organogenesis Holdings' ability to generate profits relative to its revenue, operating costs, and shareholders' equity. Below are some of Organogenesis Holdings' important valuation drivers and their relationship over time.
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
| Market Cap | 446.6M | 811.3M | 1.2B | 349.9M | 536.7M | 726.0M | |
| Enterprise Value | 487.0M | 811.6M | 1.2B | 371.2M | 551.7M | 744.2M |
Organogenesis Holdings ESG Sustainability
Some studies have found that companies with high sustainability scores are getting higher valuations than competitors with lower social-engagement activities. While most ESG disclosures are voluntary and do not directly affect the long term financial condition, Organogenesis Holdings' sustainability indicators can be used to identify proper investment strategies using environmental, social, and governance scores that are crucial to Organogenesis Holdings' managers, analysts, and investors.Environmental | Governance | Social |
Organogenesis Fundamentals
| Return On Equity | -0.0266 | ||||
| Return On Asset | 0.0164 | ||||
| Profit Margin | (0.02) % | ||||
| Operating Margin | 0.05 % | ||||
| Current Valuation | 539.66 M | ||||
| Shares Outstanding | 132.58 M | ||||
| Shares Owned By Insiders | 43.44 % | ||||
| Shares Owned By Institutions | 48.28 % | ||||
| Number Of Shares Shorted | 9.79 M | ||||
| Price To Earning | 17.12 X | ||||
| Price To Book | 1.89 X | ||||
| Price To Sales | 1.17 X | ||||
| Revenue | 433.14 M | ||||
| Gross Profit | 345.87 M | ||||
| EBITDA | 36.03 M | ||||
| Net Income | 4.95 M | ||||
| Cash And Equivalents | 113.24 M | ||||
| Cash Per Share | 0.87 X | ||||
| Total Debt | 119.35 M | ||||
| Debt To Equity | 0.52 % | ||||
| Current Ratio | 2.62 X | ||||
| Book Value Per Share | 2.10 X | ||||
| Cash Flow From Operations | 30.92 M | ||||
| Short Ratio | 23.59 X | ||||
| Earnings Per Share | (0.05) X | ||||
| Price To Earnings To Growth | 6.15 X | ||||
| Target Price | 4.7 | ||||
| Number Of Employees | 862 | ||||
| Beta | 1.6 | ||||
| Market Capitalization | 532.96 M | ||||
| Total Asset | 460.02 M | ||||
| Retained Earnings | (40.97 M) | ||||
| Working Capital | 144.53 M | ||||
| Current Asset | 24.47 M | ||||
| Current Liabilities | 23.22 M | ||||
| Net Asset | 460.02 M |
About Organogenesis Holdings Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Organogenesis Holdings's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Organogenesis Holdings using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Organogenesis Holdings based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Pair Trading with Organogenesis Holdings
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Organogenesis Holdings position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Organogenesis Holdings will appreciate offsetting losses from the drop in the long position's value.Moving against Organogenesis Stock
| 0.86 | TCHH | Trustcash Holdings | PairCorr |
| 0.79 | JNJ | Johnson Johnson Fiscal Year End 28th of January 2025 | PairCorr |
| 0.78 | PFE | Pfizer Inc Fiscal Year End 4th of February 2025 | PairCorr |
| 0.74 | MRK | Merck Company Fiscal Year End 6th of February 2025 | PairCorr |
| 0.73 | ME | 23Andme Holding | PairCorr |
The ability to find closely correlated positions to Organogenesis Holdings could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Organogenesis Holdings when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Organogenesis Holdings - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Organogenesis Holdings to buy it.
The correlation of Organogenesis Holdings is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Organogenesis Holdings moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Organogenesis Holdings moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Organogenesis Holdings can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Check out Organogenesis Holdings Piotroski F Score and Organogenesis Holdings Altman Z Score analysis. To learn how to invest in Organogenesis Stock, please use our How to Invest in Organogenesis Holdings guide.You can also try the Global Correlations module to find global opportunities by holding instruments from different markets.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Organogenesis Holdings. If investors know Organogenesis will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Organogenesis Holdings listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth 3.5 | Earnings Share (0.05) | Revenue Per Share 3.446 | Quarterly Revenue Growth 0.061 | Return On Assets 0.0164 |
The market value of Organogenesis Holdings is measured differently than its book value, which is the value of Organogenesis that is recorded on the company's balance sheet. Investors also form their own opinion of Organogenesis Holdings' value that differs from its market value or its book value, called intrinsic value, which is Organogenesis Holdings' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Organogenesis Holdings' market value can be influenced by many factors that don't directly affect Organogenesis Holdings' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Organogenesis Holdings' value and its price as these two are different measures arrived at by different means. Investors typically determine if Organogenesis Holdings is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Organogenesis Holdings' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.